8-K
filed June 18, 2026, 8:28 AM ET
ticker BFNH
CIK 0001310488
other material
confidence high
sentiment neutral
materiality 0.90
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH): M&A transaction — BioForce Nanosciences changes control; sells 79.65% stake; pivots to oil & gas
BIOFORCE NANOSCIENCES HOLDINGS, INC.
- Merle Ferguson sold 26.7M shares (79.65% of outstanding) to Nexus Capital Investments for $400,000 on April 15, 2026.
- Co-CEOs Steven Gagnon and John LaViolette, and VP Sasha Shapiro resigned effective June 17, 2026.
- Scott Mager appointed as Director effective June 15, 2026; Richard Kaiser named interim CEO.
- Company shifts business from vitamin supplements to oil and gas industry; evaluating opportunities.
Featured in Daily 8-K Digest
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Kaiser was appointed as interim Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
- Action
- appointed
- Role
- interim Chief Executive Officer
Exact text from the filing
On June 17, 2026, the Company’s Board of Directors appointed Richard Kaiser as the Company’s interim Chief Executive Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John LaViolette resigned as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
- Action
- resigned
- Role
- Co-Chief Executive Officer
Exact text from the filing
On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Mager was appointed as Director at BIOFORCE NANOSCIENCES HOLDINGS, INC..
- Action
- appointed
- Role
- Director
Exact text from the filing
Effective June 15, 2026, the Board of Directors appointed Scott Mager as Directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven Gagnon resigned as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
- Action
- resigned
- Role
- Co-Chief Executive Officer
Exact text from the filing
On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sasha Shapiro resigned as Vice-President at BIOFORCE NANOSCIENCES HOLDINGS, INC..
- Action
- resigned
- Role
- Vice-President
Exact text from the filing
On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
BIOFORCE NANOSCIENCES HOLDINGS, INC. underwent a change of control involving Nexus Capital Investments, Inc. for $400,000 (closed 2026-04-15).
- Action
- change of control
- Counterparty
- Nexus Capital Investments, Inc.
- Consideration
- $400,000
- Closing
- 2026-04-15
Exact text from the filing
April 15, 2026, Merle Ferguson (“Seller”), a current Director of the Company sold 26,700,000 shares of his common stock in the Company to Nexus Capital Investments, Inc., a Delaware Corporation (“Purchaser”). This represented Mr. Ferguson’s controlling stock interest in the Company, equalling 79.65% of the outstanding common stock of the Company. Nexus Capital Investments, Inc. paid $400,000 to the Seller from its corporate funds; no loans were involved in this transaction.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.